Unassociated Document
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934



Date of Report (Date of earliest event reported)
August 2, 2007

Pharmion Corporation
(Exact name of registrant as specified in its charter)

Delaware
   
000-50447
   
84-1521333
(State or other jurisdiction
of incorporation)
  
(Commission File
Number)
  
(IRS Employer
Identification No.)

2525 28th Street, Boulder, Colorado
                
80301
(Address of principal executive offices)
  
(Zip Code)

Registrant's telephone number, including area code
720-564-9100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item
7.01
Regulation FD Disclosure.
     
   
On August 2, 2007, Pharmion Corporation issued a press release announcing top line results of a multi-institutional, international, randomized, Phase 3 controlled trial of Vidaza® (azacitidine for injection) versus conventional care regimens in the treatment of patients with higher-risk myelodysplastic syndromes.  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
 
The information incorporated by reference in Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
     
Item
9.01
Financial Statements and Exhibits.
     
   
(d) Exhibits
     
    Exhibit  
   
Number 
 
Description
 
    99.1
Press Release, dated August 2, 2007

This exhibit is furnished pursuant to Item 7.01 and shall not be deemed to be “filed.”


SIGNATURES
 
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
PHARMION CORPORATION
 
 		  
 		  
 
 Date:  August 2, 2007 
 By:  
/s/ Steven N. Dupont 
 
Name: Steven N. Dupont
 
Title: Vice President, General Counsel and
Corporate Secretary